RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.com
Peer-Reviewed Head & Neck Oncology Journal Accepts Trimira Paper on Autofluorescent Imaging for Cancer – Autofluorescence Is at Heart of Identafi "Multispectral" Technology
HOUSTON, Nov. 9, 2009 — The growing recognition of the value of autofluorescence in detecting oral cancer is the subject of a manuscript recently accepted for publication in the peer-reviewed Head & Neck Oncology journal. Head & Neck Oncology is an open- access, peer-reviewed journal accessible at BioMed Central (www.biomedcentral.com).
Head & Neck Oncology (www.ucl.ac.uk/hnods/Head_and_Neck_Oncology), the official journal of the Head & Neck Optical Diagnostics Society, encompasses all aspects of clinical practice, basic and translational research on the aetiology, pathophysiology, diagnosis, assessment, management, follow-up, and prognosis of patients with head and neck tumors. The journal focuses on evidence-based and hypothesis-driven research, and aims to provide researchers and clinicians in the field, with practical updates at the edge of translational research.
"Incidental Detection of An Occult Oral Malignancy With Autofluorescence Imaging" is the title of the article by Nadarajah Vigneswaran of the Department of Diagnostic Sciences, The University of Texas Dental Branch at Houston, Sheila Koh of the Department of Restorative Dentistry and Biomaterials, The University of Texas Dental Branch at Houston, and Trimira® LLC scientist Dr. Ann M. Gillenwater, professor of the Head and Neck Surgery Department, The University of Texas M.D. Anderson Cancer Center.
Gillenwater at M.D. Anderson, working with researchers at Rice University, pioneered the clinical work in the initial development of a breakthrough "multispectral" optical system that uses both fluorescence and reflectance lightwaves to detect cancer.
"Light-induced tissue fluorescence visualization technologies are being used increasingly as noninvasive diagnostic aids" states the paper, which illustrates the important role played by autofluorescence tissue-imaging in diagnosing cancer. In the case cited, a tumor that appeared clinically innocuous and otherwise would not have been biopsied was flagged as meriting further scrutiny following a screening using a multispectral oral cancer detection device from Trimira® LLC, Autofluorescence indicated malignancy, and a biopsy confirmed the presence of a metastatic squamous cell carcinoma. Trimira® LLC's award-winning oral cancer screening tool is Identafi® 3000 ultra — the only multispectral oral cancer detection device on the market.
Created expressly for intraoral use, Trimira® LLC's cordless Identafi® 3000 ultra is small, lightweight, portable, and ergonomically shaped. It incorporates a nickel-plated design that improves durability and delivers a smoother feel. The handheld is portable, and thus is readily moved from room to room and patient to patient.
Identafi® 3000 Ultra
Identafi® 3000 ultra's high-speed, high-resolution, triple-wavelength spectroscopy is highly effective in screening oral cancers; the same science works in diagnosing cervical, skin, gastrointestinal, and bladder cancers. Developed by three institutions — The University of Texas, M.D. Anderson Cancer Center; Rice University; British Columbia Cancer Research Centre — it is a new and powerful technology for the visualization of mucosal abnormalities, including cancer or premalignant dysplasia.
Intended for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians, Identafi® 3000 ultra features brilliant white, violet, and green-amber illumination. Its patented multispectral technology minimizes false positives and reveals abnormalities in oral tissue missed by the naked eye. Unlike other methods, Identafi® 3000 ultra empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. Identafi® 3000 ultra's violet wavelength capability was cited in the May 2009 issue of Cancer Prevention Research, the journal of the American Association for Cancer Research, as the best excitation wavelength to discriminate between neoplastic and non-neoplastic tissue areas. Identafi® 3000 ultra delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care.
About Trimira LLC
Trimira® LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm®, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm®'s core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira® at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
